ANTX earnings analysis
What we found in ANTX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
AN2 reported second-quarter EPS of -$0.18, while revenue, margins, and free cash flow were not disclosed in the provided filing extract. The six-month net loss widened to $18.2 million from $17.1 million, and previously identified material weaknesses in financial reporting remained unresolved as of June 30, 2026. Liquidity totaled $79.9 million and is expected to fund operations for at least 12 months, but management acknowledges the need for substantial additional funding, creating dilution and execution risk.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- $79.9M Liquidity Balance
- Cash, cash equivalents, and investments totaled $79.9 million as of June 30, 2026, primarily in money market funds and investment-grade fixed-income and government securities.
- Six-Month Loss Increased
- The six-month net loss was $18.2 million versus $17.1 million in the comparable 2025 period, an unfavorable increase of $1.1 million, or approximately 6.4%.
- At Least 12 Months of Funding
- Management states that existing cash, cash equivalents, and investments will fund operating expenses and capital expenditure requirements for at least the next 12 months.
- $80.0M ATM Capacity
- The company retains an at-the-market facility permitting sales of up to $80.0 million of common stock, providing additional financing capacity if needed.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Material Weaknesses Persist
- Disclosure controls and procedures were not effective as of June 30, 2026 because previously identified material weaknesses in financial reporting and IT general controls continue to exist. The deficiencies could result in misstatements affecting all financial statement accounts and disclosures.
- Future Capital Requirement
- The company states that substantial additional funding will be required, despite $79.9 million of cash, cash equivalents, and investments at June 30, 2026. Failure to raise capital could delay, reduce, or terminate development programs.
- Dilution From Equity Financing
- Potential dilution remains material: the company may sell up to $80.0 million of common stock under its ATM facility, while approximately 8.7 million pre-funded warrants remain outstanding and could result in additional shares.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.18
What they said about what is next.
No quantitative revenue or EPS guidance was provided. Management states that existing cash, cash equivalents, and investments are expected to fund operating expenses and capital expenditure requirements for at least the next 12 months; the report does not provide a longer-term numeric cash runway.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 11, 2026
- AN2 Therapeutics reported a net loss of $10.0 million for Q1 2026, a slight improvement compared to a $10.6 million loss in Q1 2025. The company's cash position remains strong at $85.3 million, sufficient for operations…
- 10-K · March 17, 2026
- AN2 is a pre-revenue, clinical‑stage small‑molecule company focused on boron chemistry; the 10‑K emphasizes pipeline expansion with multiple Phase 2 starts planned in 2026 and several near‑term data catalysts. The…
- 10-Q · August 12, 2025
- AN2 reported a materially narrower quarterly loss as operating expenses fell sharply: net loss for Q2 2025 was $6.462 million (EPS $(0.21)) versus $14.435 million (EPS $(0.48)) in Q2 2024. Total operating expenses…
- 10-Q · May 13, 2025
- AN2 reported a narrower net loss in Q1 2025 as operating spend declined materially; net loss was $10,649 (three months ended March 31, 2025) vs $16,617 in Q1 2024 and diluted loss per share improved to $(0.35) from…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ANTX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever